Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Prescription Drug User Fee Act | Statement: [Food and Drug Administration Modernization Act of 1997, relatedTo, Prescription Drug User Fee Act]

Target entity: Prescription Drug User Fee Act
Context triple: [Food and Drug Administration Modernization Act of 1997, relatedTo, Prescription Drug User Fee Act]

• A. Prescription Drug User Fee Act of 1992 chosen
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• B. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• C. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• D. Medicare Prescription Drug, Improvement, and Modernization Act of 2003
  The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
• E. Food and Drug Administration Modernization Act of 1997
  The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
• F. None of above.
• G. Unsure - the case is ambiguous/there is not enough information to decide.